These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
Wells Fargo raised the firm’s price target on Axsome Therapeutics (AXSM) to $160 from $140 and keeps an Overweight rating on the shares. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback